Adrenomedullin (ADM) in the human forearm vascular bed: effect of neutral endopeptidase inhibition and comparison with proadrenomedullin NH2‐terminal 20 peptide (PAMP)
Open Access
- 1 August 2001
- journal article
- clinical trial
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 52 (2) , 159-164
- https://doi.org/10.1046/j.0306-5251.2001.1420.x
Abstract
Aims To compare the haemodynamic responses of proadrenomedullin N‐terminal 20 peptide (PAMP) and adrenomedullin (ADM) in the forearm vascular bed of healthy male volunteers, and to investigate the role of neutral endopeptidase (NEP) in the metabolism of ADM. Methods On two separate occasions, ADM (1–30 pmol min−1) and PAMP (100–3000 pmol min−1) were infused into the brachial artery of eight male subjects, and forearm blood flow (FBF) assessed using venous occlusion plethysmography. In a second study, eight male subjects received the same doses of ADM, co‐infused with either the NEP inhibitor thiorphan (30 nmol min−1) or the control vasoconstrictor noradrenaline (120 pmol min−1), on separate occasions. Both studies were conducted in a double‐blind, randomized manner. Results ADM and PAMP produced a dose‐dependent increase in FBF (P ≤ 0.002). Based on the dose producing a 50% increase in FBF, ADM was ∼60 times more potent than PAMP. Thiorphan and noradrenaline produced similar reductions in FBF of 14 ± 4% (mean ± s.e. mean) and 22 ± 6%, respectively (P = 0.4). However, the area under the dose–response curve was significantly greater during co‐infusion of ADM with thiorphan than with noradrenaline (P = 0.028), as was the maximum increase in FBF ratio (2.1 ± 1.0 vs 1.2 ± 0.2; P = 0.030). Conclusions ADM and PAMP both produce a local dose‐related vasodilatation in the human forearm, but PAMP is ∼60 times less potent than ADM. In addition, NEP inhibition potentiates the haemodynamic effects of ADM. These findings suggest that PAMP may not play a role in the physiological regulation of blood flow. However, in pathophysiological conditions such as hypertension and heart failure, NEP inhibition may exert a beneficial effect by increasing the biological activity of ADM.Keywords
This publication has 42 references indexed in Scilit:
- Comparison of vasodilator potency of adrenomedullin and proadrenomedullin N-terminal 20 peptide in humansLife Sciences, 1999
- Elevation of circulating proadrenomedullin‐N terminal 20‐peptide in thyrotoxicosisClinical Endocrinology, 1997
- Hypotensive Effect of a Newly Identified Peptide, Proadrenomedullin N -Terminal 20 PeptideHypertension, 1996
- Proadrenomedullin N-Terminal 20 Peptide Is Rapidly Cleaved by Neutral EndopeptidaseBiochemical and Biophysical Research Communications, 1996
- Receptors for adrenomedullin in human vascular endothelial cellsEuropean Journal of Pharmacology: Molecular Pharmacology, 1995
- Synthetic human adrenomedullin and adrenomedullin 15-52 have potent short-lived vasodilator activity in the hindlimb vascular bed of the catLife Sciences, 1994
- Identification and hypotensive activity of proadrenomedullin N-terminal 20 peptide (PAMP)FEBS Letters, 1994
- Adrenomedullin: A Novel Hypotensive Peptide Isolated from Human PheochromocytomaBiochemical and Biophysical Research Communications, 1993
- Effect of local intra-arterial NG-monomethyl-L-arginine in patients with hypertensionJournal Of Hypertension, 1992
- Hemodynamic Effects of Bradykinin on Systemic and Pulmonary Circulation in Healthy and Hypertensive HumansJournal of Cardiovascular Pharmacology, 1990